Devolution
2 años hace
I think upon merger and renaming to Profusa, there will be about 100 million shares.
Since the target is known by the market, and the stock is now trading at a 52 week high of $10.05 (average volume under 11,000 shares per day, often times trades in the single digits or not at all on any given day), then I am convinced the pps will be above $10 per share upon merger ? I mean, why would anyone pay $10 a share now if they didn't believe that this had room to go upward?
The Lumee, when it gets its FDA approval (figure June 2023?) will compete with...or replace...Dexcom's G6 and/or Abbott's Freestyle Libre 2, both of which are big, clumsy, and have to be moved every 2 weeks.
Even my fairly inactive brother-in-law complains that he is always knocking his off, especially at night.
Check out DXCM's 5 year chart, just for sh$ts and giggles.
I know, apples to oranges, but there might be some long term potential there.
Devolution
2 años hace
CE Mark: The EU consists of 28 countries with 750 million people.
Profusa has a CE Mark for Lumee in the EU, but for detecting Oxygen levels:
https://profusa.com/profusa-receives-cemark/
Certainly, if applying for Lumee 510K for glucose levels (and most likely oxygen levels as well) in the US, then Profusa will undoubtedly do the same in the EU.
In September, 2013, Dexcom was trading at just above $10 per share.
By 2022, it had a 52 week high of $164.86. It is trading was trading at $112.61 today (11/17/22) with 386 million shares outstanding, Market Cap = almost $44 billion.
After the merger, I am roughly estimating that the new company will have about 75 to 100 million shares.
Devolution
2 años hace
Peter O'Rourke (born January 3, 1966): 56 years old, currently Chairman of the Board of NorthView Acquisition Corp. Since December 2018, Mr. O’Rourke has served as Managing Partner at TCI Partners, a consulting firm focused on healthcare, aerospace and the public sector. From January 2017 to December 2018, Mr. O’Rourke served as the Acting Secretary and Chief of Staff of the Department of Veteran Affairs under Donald Trump. From May 2015 to July 2016, Mr. O’Rourke served as a principal of Calibre Systems, Inc., a consulting firm. Mr. O’Rourke also served both U.S. Navy and Air Force. Mr. O’Rourke received a Bachelor of Arts in Political Science from the University of Tennessee in Knoxville as well as a Master of Science in Logistics and Supply Chain Management from the United States Air Force’s Institute of Technology. He previously worked in various positions in government consulting, including as a congressional staffer for U.S. Representative Tom Latham, and he also served as the executive director of the Republican Party of Florida.
Peter joined Axim's Board of Director's on July 21, 2020.
In April, 2021, Peter formed the SPAC North View Acquisition Corp., which began selling shares in December of 2021. On November 7, 2022, NVAC announced its intent to merge with Profusa, a company pioneering a novel, innovative approach to accurately, efficiently, and easily measure various biochemistry markers in real time using the Lumee hydromicrofiber.
In the European Union, the Lumee Oxygen Platform is CE Marked (January 28, 2020). In the United States, the Lumee Oxygen Platform is an Investigational Device Limited by Federal Law to Investigational Use.
The goal of the merger is to turn Profusa into a publicly traded entity by the first quarter of 2023, and thereafter to seek FDA approval for Lumee in the United States.
Lumee is a biosensor micro fiber that can immediately measure oxygen levels, glucose levels, exposure to biochemicals, even early signs of influenza - almost any biomarker of interest found in intercellular fluid without the "old technology way" of pin pricking and drawing blood.
In 2016, DARPA and the U.S. Army Research Office (ARO) awarded Profusa a $7.5 million dollar grant to develop the company’s implantable biosensors for the simultaneous, continuous monitoring of multiple body sensors. Profusa has focused research and product development on providing real-time monitoring of a combat soldier’s health status to improve mission efficiency and overall performance, partnering with DARPA to create breakthrough technologies and capabilities for our national security.
Peter O'Rouke's close ties to the US government for years is a nice match for Profusa's Lumee Military applications and its ultimate movement into civilian applications.
Currently, devices such as Abbott's Freestyle Libre 2 and Dexcom's G6 are expensive and must be moved every two weeks (to prevent rejection by the body).
Devolution
2 años hace
Profusa:Breaking the Biocompatibility Barrier
Profusa’s unique bioengineering approach overcomes the largest hurdle in long-term use of biosensors in the body: the foreign body response. Approximately 5 mm long and 500 microns in diameter, each tiny biosensor is a soft, flexible fiber designed to be biologically compatible with the body’s tissues for continuous monitoring, while overcoming the effects of local inflammation or rejection
Tissue-integrating Scaffold
Providing medical-grade data, the biosensor is made of a porous “smart gel” that mimics the 3D microenvironment of cells. The smart gel is linked to a light-emitting molecule that emits a fluorescent signal in the presence of one or more body chemicals such as oxygen, glucose, lactate, or other biomarker.
Optical Reader
Adhered to the skin’s surface or held by hand, a separate optical reader is used to read the fluorescent signal from the embedded biosensor. The reader sends excitation light through the skin to the biosensor, which then emits fluorescent light proportional to the amount of biochemical measured.
Adaptable Form Factor for Consumer and Medical Applications
Profusa’s technology platform enables the development of biosensor systems with a variety of form factors serving consumer as well as medical applications for continuous monitoring of body chemicals. Results from the optical reader are designed to be transmitted to a smart phone application that allows the user to make actionable decisions, from improving their general health and well-being, to taking their athleticism to another level, or managing a chronic disease such as diabetes or COPD. Data can be shared securely via HIPAA-compliant digital networks with healthcare providers and public health analysts conducting longitudinal studies.
Devolution
2 años hace
Abbott Laboratories (NYSE:ABT), DexCom (NASDAQ:DXCM) Medtronic (NYSE:MDT) appear to be the leaders in the blood sugar testing market among listed companies as they have a number of popular products in circulation under multiple brands.
Abbott’s FreStyle Libre, Medtronic’s Guardian Connect and DexCom’s G6 provide the wearable continuous monitoring like the Lumee, while private competitor Ascensia has a similar device.
As such, although these competitors don’t appear to have the same government backing, they do have a head start and significant resources at their disposal. Even these smallest of the group, DexCom, has a $44 billion market cap.
Profusa may be able to rake in recurring government revenues down the road from its devices, but it has to get commercialized and the chips in the population first.
...the Lumee came out of DARPA’s SIGMA+ program. This program was set up to fund projects designed to expand US national defense institutions’ “advance capability to detect illicit radioactive and nuclear materials by developing new sensors and networks that would alert authorities to chemical, biological, and explosives threats as well.”
Effectively, SIGMA+ is hoping to use connected humans as a “a common network infrastructure” and therefore allow governments to react to “chemical, biological, radiological, nuclear and high-yield explosive” attacks the way network operators respond to cyberattacks – in theory, anyway.
Phase I of this program is to develop the sensors, while the second phase is to focus on “network development, analytics and integration” of the connected humans. This may sound like a Bond movie plot, but, to Profusa’s credit, it has been open about its government ties from the start. In fact, Profusa Software and Systems Lead Keven Zhao was named a DARPA Riser in 2018.
Devolution
2 años hace
Looks like the acquisition target was selected:
https://finance.yahoo.com/news/profusa-inc-digital-health-company-210000399.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAANeN6yZgDtAoUaydfITlBOpJsr1FivrVYFEDbH0zvaD_BorKQECYT6zI5zrtkLEvnUAgwSrdOdG9x8c5V7UEO_F7YHSQlK18wLno46-aR8jvSfBQlt8o-BO2pq3qE3QoW5RkfHnGgbV8iYv5e5hBkf9Qiq2aFPfk9S3J_pr-jNZg
Oddly announced on November 7th, when everyone was more likely focused on the November 8th midterm elections.
Profusa is based in Emeryville, CA and is a digital health company that is pioneering the next generation of personalized medicine via the development of novel tissue-integrated biosensors.
Profusa took 9 years to develop a micro hydrogel fiber, 3mm by .5 mm, that can be inserted under the skin. The beauty is that this micro fiber does not elicit an immune response from the body, is super small and practically non detectable and can last for many months at a time (ease of deployment and long-term functionality), and uses light emitting fluorescent molecules to continuously analyze concentrations of whatever it is that you want to measure (oxygen levels, glucose, etc.). The individual can use a simple phone app to monitor their own levels, and send those readings to medical professionals in remote locations, with real time accuracy.
Profusa already has a CE Mark in Europe for "Lumee Oxygen Platform", and with this merger, will now be seeking FDA approval for its continuous glucose monitoring (CGM) micro fiber implant. The CGM market is expected to grow, worldwide, from $6.13 billion in 2021 to $16.33 billion by 2030, a compound annual growth rate of 17.33%
Current NVAC shareholders will own 41.3% of the combined company.
I am certainly impressed with Peter O'Rouke's decision. Profusa looks like the "better mouse trap" with an untold number of potential uses.
I can see the similarity in thinking between this and AXIM, in that Axim's reader would be equivalent to the micro hydrogel fiber. Both can be tweaked ("programmed") to read whatever you are looking for, easily and fairly inexpensively, both would give accurate and rapid results, and both have global marketing potential.
Devolution
2 años hace
If you choose to buy, then it is most practical to buy the Rights (NVACR) in units of 10 to avoid wasting $s on fractions that won't be converted to shares...but there will be time.
NVACR won't be converted to shares until well after the announcement, because first the shareholders have to approve (vote on) the selected target.
There is always the risk that a target is not selected and the $ is returned (March of 2023), and in that case the warrants and the rights would expire worthless!
With a price target of above $11.50 for the warrants, NVAC would have to be selling above that price in order for the warrants to have any value.
The risk/reward is like this: If NVAC is trading at $14, then a 10 cent purchase of a share of NVACW would net a profit of $14 - $11.50, or $2.50 (less of course your 10 cent initial investment). Quite a nice return (almost 2,500%) if you have the stomach to weather the risk.
The Rights are less risky, in that they have value even if NVAC is below $11.50 (or $11,60, the point at which the warrants are worth what you originally paid for them - 10 cents), but the ROI for the Rights drops off quickly (in comparison to the warrants) if/when NVAC goes above $11.60.
If my math is correct, and if right now warrants and rights can each be purchased for 10 cents, then the ROI between the two is equal if NVAC is at $12.67. Anything above that, and the warrants would have been the better choice, as the ROI increases much more rapidly for the warrants than the rights.
The conversion to shares will occur when the deal (take over) is consummated, but I do feel that the value of NVAC, NVACR, and NVACW should appreciate nicely upon the target announcement and the period leading up to the finalization of the deal - if such events occur.
Godspeed.
Devolution
2 años hace
The only "excuses" for not announcing that I can come up with are "the economy" and "politics".
Generally speaking, stocks are down everywhere, the economy is heading into a recession (if not there already) , and the saying "sell in May and go away" doesn't conclude until mid-September.
Add to that the political environment, whereby this administration now has the lowest approval rate of any President (ever), and perhaps this isn't the right time to do an announcement.
NVAC has until March of 2023. I'm hoping all the above changes 180 degrees by the end of this year, soon after the Red Tsunami that I believe most now are convinced is coming.
I personally believe the above discussion is effecting the majority of stocks right now, including AXIM.
...this is all just going to lead into a "Yuge" reverse pendulum swing by the time DJT announces his intentions...
Devolution
3 años hace
Lol, I believe you are suggesting that the rover is moving in a large circle, as 360 degrees brings you back to where you started...assuming, of course, that the drift rate is a constant of 1 degree per hour AND always in the same direction.
REVEALING the locations where the ballots were picked up would be awesome (I believe, Stacy Abrams of GA was heavily involved).
I think identifying the mules to law enforcement for prosecution is another first step that should be taken. Certainly the mules will do a lot of talking. Once enough of that occurs, and those who orchestrated the criminal syndicate are indicted and prosecuted, then the next step is decertification.
Devolution
3 años hace
Lol, I have kind of been using this board as my personal diary, as you can tell by me being the only one posting.
I'd hate to inadvertently bring JaneyH, M73, 24, or worst of all, Tiresias over here.
If you have a way to privately reach out to serious poster and wish to do so, then certainly be my guest.
With the dismal performance of Axim these days, I'm not so sure anyone wants to look at something somewhat related (ie: Peter O'Rourke is a founder of NVAC AND is on the board at Axim).
Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Blue Skys
5 meses hace
TexasMarvL
7 meses hace
Hot Features
Premium
